Clinical trial · Observational
Prospective Bladder Cancer Infrastructure (ProBCI)
Prospective Bladder Cancer Infrastructure: an Infrastructure for Observational and Interventional Bladder Cancer Research (ProBCI)
NCT04503577CI-TRIAL-00093394ProBCIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Bladder cancer patients
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 10 years
- description
- Alive/death/emigrated
Secondary outcomes (4)
- measure
- Progression-free survival
- timeFrame
- 10 yeas
- description
- Progression/no progression
- measure
- Recurrence-free survival
- timeFrame
- 10 yeas
- description
- Recurrence/no recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Bladder cancer * Any stage except Ta * 18 years or older * Written informed consent Exclusion Criteria: * No exclusion criteria Note: participation in ProBCI does not exclude the patient from participation in other studies.
References
Publications (2)
- DERIVEDRichters A, Meijer RP, Mehra N, Boormans JL, van der Heijden AG, van der Heijden MS, Kiemeney LA, Aben KK. Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI. BMJ Open. 2021 May 18;11(5):e047256. doi: 10.1136/bmjopen-2020-047256. PMID 34006553
- DERIVEDRichters A, Mehra N, Meijer RP, Boormans JL, van der Heijden AG, Smilde TJ, van der Heijden MS, Kiemeney LA, Aben KK. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25:100266. doi: 10.1016/j.ctarc.2020.100266. Epub 2020 Dec 8. PMID 33316557